Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial
-
Published:2024-07
Issue:10450
Volume:404
Page:337-338
-
ISSN:0140-6736
-
Container-title:The Lancet
-
language:en
-
Short-container-title:The Lancet
Reference3 articles.
1. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial;Rugo;Lancet,2023
2. Talking about toxicity – “what we’ve got here is a failure to communicate”;Sacks;N Engl J Med,2019
3. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial;Janjigian;Lancet,2021